Exploring Outcomes and Characteristics of Myasthenia Gravis 2

Active, not recruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

January 12, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Myasthenia Gravis
Interventions
OTHER

Blood sample

Each blood draw will involve removing approximately 75 mL (5 tablespoons) of blood

Trial Locations (10)

20037

George Washington University, Washington D.C.

27157

Wake Forest University, Winston-Salem

27599

University of North Carolina, Chapel Hill

27710

Duke University Medical Center, Durham

29425

Medical University of South Carolina, Charleston

60637

University of Chicago, Chicago

90048

Cedars Sinai Medical Center, Los Angeles

92697

University of California-Irvine, Irvine

06519

Yale University, New Haven

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Yale University

OTHER